The pharmaceutical landscape is currently witnessing a tectonic shift. For decades, the “occupancy-driven” model—where a small molecule sits in a protein’s active site to inhibit its function—has been the gold standard. However,Read More…
In the rapidly evolving landscape of modern pharmacology, we are witnessing a fundamental shift from “blocking” to “destroying.” For decades, the pharmaceutical industry relied on the occupancy-driven model—small molecules designed to sitRead More…
For decades, drug discovery has been somewhat limited by the “lock and key” paradigm. Small molecule inhibitors required a deep, well-defined pocket on the target protein’s surface to bind effectively and blockRead More…
In the vast landscape of drug discovery, a paradigm shift is underway. For decades, the “occupancy-driven” model has dominated the field—the idea that to treat a disease, a small molecule must bindRead More…
In the complex landscape of oncology, few challenges are as daunting as treating cancer that has metastasized to the brain. For patients and researchers alike, the blood-brain barrier—a protective shield that preventsRead More…
The landscape of cancer treatment is undergoing a fundamental shift, moving beyond traditional methods of protein inhibition toward a more profound and comprehensive therapeutic strategy: targeted protein degradation (TPD). This innovative approachRead More…
Endocrine therapy has long been a vital treatment option for estrogen receptor-alpha (ERα)-positive breast cancer. However, the frequent clinical problem of endocrine therapy resistance has left many patients in a difficult situation. This is particularly true whenRead More…
For decades, the primary strategy in drug development has been one of inhibition. We design molecules to block the function of harmful proteins, fitting into their active sites like a key inRead More…
Proteolysis-targeting chimeras function by recruiting ubiquitin ligases to targeted intracellular proteins, which promotes the degradation of pathogenic proteins via the proteasome system. This has made many previously “undruggable” proteins into viable therapeuticRead More…
In the ever-evolving landscape of medical research, protein degraders have emerged as a revolutionary class of therapeutic agents. Targeted protein degradation has rapidly expanded as a promising approach in drug discovery, openingRead More…